Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | subfamily A22A unassigned peptidase (A22 family) | 0.0463 | 0.0494 | 0.0394 |
Loa Loa (eye worm) | gamma-secretase subunit pen-2 | 0.0434 | 0.0447 | 0.0447 |
Trichomonas vaginalis | Clan AD, family A22, presenilin-like aspartic peptidase | 0.0463 | 0.0494 | 1 |
Brugia malayi | Presenilin family protein | 0.0463 | 0.0494 | 0.0494 |
Trichomonas vaginalis | Clan AD, family A22, presenilin-like aspartic peptidase | 0.0463 | 0.0494 | 1 |
Loa Loa (eye worm) | gamma-secretase subunit aph-1 | 0.6247 | 1 | 1 |
Trypanosoma cruzi | Aph-1 protein, putative | 0.2434 | 0.3734 | 1 |
Echinococcus multilocularis | presenilin | 0.0463 | 0.0494 | 0.0394 |
Brugia malayi | gamma-secretase subunit pen-2 | 0.0434 | 0.0447 | 0.0447 |
Trichomonas vaginalis | Clan AD, family A22, presenilin-like aspartic peptidase | 0.0463 | 0.0494 | 1 |
Echinococcus multilocularis | gamma secretase subunit aph 1 | 0.6247 | 1 | 1 |
Schistosoma mansoni | gamma-secretase subunit aph-1 | 0.6247 | 1 | 1 |
Brugia malayi | hypothetical protein | 0.0225 | 0.0104 | 0.0104 |
Loa Loa (eye worm) | hypothetical protein | 0.0225 | 0.0104 | 0.0104 |
Trypanosoma brucei | Aph-1 protein, putative | 0.2434 | 0.3734 | 1 |
Entamoeba histolytica | presenilin 1 peptidase, putative | 0.0463 | 0.0494 | 0.5 |
Leishmania major | presenilin-like aspartic peptidase, putative,presenilin-like aspartic peptidase, clan AD, family A22A, putative | 0.0463 | 0.0494 | 0.5 |
Echinococcus granulosus | gamma secretase subunit aph 1 | 0.6247 | 1 | 1 |
Echinococcus granulosus | presenilin enhancer 2 | 0.0434 | 0.0447 | 0.0347 |
Echinococcus granulosus | presenilin | 0.0463 | 0.0494 | 0.0394 |
Toxoplasma gondii | hypothetical protein | 0.0162 | 0 | 0.5 |
Echinococcus multilocularis | presenilin enhancer 2 | 0.0434 | 0.0447 | 0.0347 |
Trypanosoma cruzi | Aph-1 protein, putative | 0.2434 | 0.3734 | 1 |
Brugia malayi | hypothetical protein | 0.0225 | 0.0104 | 0.0104 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.